Psychedelics

490 posts
German flag with cannabis plant

Cannabis stock HYTN climbs higher after German supply deals

On Friday, manufacturer HYTN Innovations (CSE:HYTN) signed supply agreements for a minimum of 4,000 kg of cannabis for the German market.
Happy Caps 2 kg Mushroom Home Grow Kit

Red Light Holland expects new mushroom grow kit order from Costco

Red Light Holland receives an informal projection from Costco Canada outlining a 20,160 unit order of Happy Caps Mushroom Home Grow Kits.
Psychedelic pills

Canadian psychedelic stock to supply MDMA to Yale

Canadian psychedelic stock PharmAla Biotech (CSE:MDMA) is up after signing a contract to supply MDMA for a clinical trial at Yale University.
MindBio Therapeutics chief executive officer Justin Hanka.

MindBio advances world-first psychedelic microdosing clinical trials

MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
Psilocybin mushrooms

Optimi will test its psilocybin on frontline healthcare workers

Health Canada clears psychedelics stock Optimi Health (CSE:OPTI) to test its psilocybin on frontline healthcare workers.
A hand holding blocks that spells out PTSD

Optimi Health ships first MDMA capsules to Australia to treat PTSD

Optimi Health (CSE:OPTI) reveals it has completed the inaugural export of its GMP-validated MDMA capsules to Australia.

MindBio’s microdosed LSD reduces depression post treatment

MindBio (CSE:MBIO), a psychedelic healthcare stock, reports a sustained 65% reduction in depressive symptoms in its phase 2A clinical trial.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.
Red Light Holland

Red Light Holland completes psilocybin extraction report

Red Light Holland (CSE:TRIP) reveals it has successfully completed the comprehensive extraction protocol with PharmAla Biotech (CSE:MDMA).

FDA committee rejects MDMA drug, discounting psychedelic stocks

A committee of the U.S. FDA rejects a drug application to treat PTSD using MDMA-assisted therapy, causing numerous stocks to fall.

Record monthly revenue positions edibles company for success

Canadian cannabis edibles are generating traction and Indiva (TSXV:NDVA) remains poised to capitalize on this ever-growing industry.

Optimi Health cleared to supply MDMA and psilocybin worldwide

Optimi Health (CSE:OPTI) earns a Health Canada Drug Establishment Licence to produce and sell its MDMA and psilocybin capsules in Australia.

Numinus approved for pioneering MDMA-based clinical trial

Numinus Wellness (TSX:NUMI) receives Health Canada approval for a clinical trial examining group models in MDMA-assisted psychotherapy.

Red Light Holland and PharmAla notch psilocybin extraction

Red Light Holland (CSE:TRIP) reveals it has successfully completed the first phase of psilocybin extraction to PharmAla Biotech (CSE:MDMA).
Optimi Health mushrooms

Optimi Health to advance psychedelic clinical trials

Optimi Health (CSE:OPTI) signs letter of intent with ATMA Journey Centers to advance its psilocybin extract into a psilocybin clinical trial.

Optimi Health certified for increased MDMA capsule dosages

Optimi Health (CSE:OPTI) confirms its formulated MDMA meets Good Manufacturing Practice specifications after third-party laboratory testing.